News & Press Releases
NewsroomKeep up with the latest news from Anocca
Press releases
Anocca säkrar 25 miljoner euro från Europeiska investeringsbanken (EIB) för att stödja klinisk utveckling av nästa generations T-cellsterapier för cancer
Södertälje, 21 december 2022 – Anocca, ett helt integrerat bioteknikföretag för utveckling av T-cellsbehandlingar, meddelade idag att det har säkrat 25 miljoner EUR i form av riskkapitallån från Europeiska investeringsbanken (EIB). Denna betydande investering visar på...
Anocca secures EUR 25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer
Södertälje, Sweden, 21 December 2022 – Anocca, a fully integrated cell therapy biotechnology company, today announced that it has secured EUR 25 million Venture Debt financing from the European Investment Bank (EIB). This significant investment recognises the strength...
Renowned Immunotherapy Expert Dr. Michael Kalos joins Anocca’s Scientific Advisory Board
Södertälje, Sweden, 7th April 2022 – Anocca, a biotechnology company using its precision biology platforms to engineer a broad portfolio of innovative T cell therapeutics, today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB). Dr....
Anocca Appoints New Senior Management Roles and Expands Scientific Teams
Södertälje, Sweden, February 22, 2022 – Anocca AB, a pioneer in T cell immunotherapy, today announces it has made a number of appointments to expand its senior leadership team and strengthen its business development and R&D capabilities. This includes the...
Anocca appoints Jacob Michlewicz as CFO
Södertälje, Sweden, 8 September 2021 – Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics, today announced the appointment of Jacob Michlewicz as Chief Financial Officer, effective immediately, and based at...
Anocca utser Jacob Michlewicz till CFO
Södertälje, 8 september 2021 – Anocca AB, ett världsledande svenskt bioteknikbolag för utveckling av T-cellsbehandlingar mot cancer, autoimmuna sjukdomar och virusinfektioner, tillkännagav idag utnämningen av Jacob Michlewicz till CFO, med omedelbar verkan. Han är...
Anocca raises $47m in a Series B Financing to advance its industrialised approach to TCR-T cellular immunotherapy
Södertälje, Sweden, 22 July 2021 – Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics for cancer, today announced the closing of a USD 47 million (SEK 400 million) Series B financing to further advance the...
Anocca reser 400 miljoner kronor för att accelerera sin portfölj av T-cellsbaserade cancerbehandlingar
Södertälje, 22 juli 2021 – Anocca AB, ett världsledande svenskt bioteknikbolag för utveckling av T-cellsbehandlingar mot cancer, autoimmuna sjukdomar och virusinfektioner, meddelade idag att bolaget har stängt en serie B-finanseringsrunda på 400 miljoner kronor (47...
Anocca in the news
Cell & Gene Therapy Insights – How to secure & standardize your cell expansion
Originally published in Cell & Gene Therapy Insights Read the transcript of David McCall, Editor, BioInsights speaking to Paula Villaescusa Sánchez, Field Application Specialist, CGT, Cytiva and Anocca's Head of GMP Process Development, Anette Brass, which...
Anocca: Standardizing TCR cell therapy design
Originally published in BioCentury. Anocca is using engineered human cells to recapitulate the T cell immune system ex vivo, eliminating the person-to-person variability in working with primary T cells from patients, to create standardized, scalable TCR-modified T...
Anocca Appoints Leading Strategic and Operational Global Drug Developer Sandra Bevan as Head of Clinical Development
Södertälje, Sweden, 9 November 2021 – Anocca AB, a leader in unlocking the potential of T cell immunotherapy to deliver transformative T cell receptor engineered T cell therapeutics (TCR-T), today announced it has appointed a new Head of Clinical Development, Sandra...
Europe’s TCR Therapy Scene Gains Traction with €40M Series B
Originally published in Labiotech.eu. Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum. Last year was a busy one for companies...
Anocca closes $47M series B round to move TCR-T cell therapies toward the clinic
Originally published in BioWorld. DUBLIN – Anocca AB raised $47 million in a series B round to advance its T-cell-based immunotherapies expressing recombinant T-cell receptors (TCRs) toward clinical trials in cancer and to build out its manufacturing capacity...
Anocca To Reach Clinical-Stage With T-Cell Therapies After Series B Injection
Originally published in Scrip. SWEDEN-BASED ANOCCA AB WILL USE A just completed $47m Series B financing to advance its industrialised cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells...
After slicing and dicing TCRs for 8 years, Swedish biotech reloads to angle for a spot in crowded cell therapy space
Originally published in Endpoints News. Södertälje, Sweden, the historic home to the Astra half of AstraZeneca, may seem an unlikely place for cutting-edge R&D on T cell receptors and cell therapies. And Reagan Jarvis — a transplant from New Zealand who had...
Reports & Regulatory press releases
Protokoll från årsstämman 2022
Klicka på länken nedan för att ladda ned protokoll från Anocca AB årsstämma 2022. Stämmoprotokoll Anocca AB 2022
Kallelse till årsstämma i Anocca AB
Aktieägarna i Anocca AB (publ) kallas härmed till årsstämma tisdagen den 21 juni 2022 kl. 10.30 på bolagets kontor med adress Forskargatan 20G, Södertälje (byggnad 212). Rätt till deltagande och anmälan Rätt att delta vid årsstämman har den aktieägare som dels är...
Årsredovisning 2021
Klicka på länken nedan för att ladda ned Anocca AB årsredovisning för 2021. Årsredovisning Anocca AB 2021
